Romiplostim use in pregnant women with immune thrombocytopenia

Treatment for immune thrombocytopenia (ITP) in pregnancy is hampered by the lack of fetal safety evidence of maternally‐administered medications. The Pregnancy Surveillance Program (PSP) collected patient information from 2017–2020 for pregnancy, birth outcomes, and adverse events (AEs) for 186 wome...

Descripción completa

Detalles Bibliográficos
Autores principales: Bussel, James B., Cooper, Nichola, Lawrence, Tatiana, Michel, Marc, Vander Haar, Emilie, Wang, Kejia, Wang, Hongmei, Saad, Hossam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091785/
https://www.ncbi.nlm.nih.gov/pubmed/36156812
http://dx.doi.org/10.1002/ajh.26743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091785/
https://www.ncbi.nlm.nih.gov/pubmed/36156812
http://dx.doi.org/10.1002/ajh.26743

Ejemplares similares